Endonovo Therapeutics, Inc. Stock price

Equities

ENDV

US29272H3003

Biotechnology & Medical Research

Market Closed - OTC Markets 03:54:48 2024-03-28 pm EDT 5-day change 1st Jan Change
0.0031 USD +34.78% Intraday chart for Endonovo Therapeutics, Inc. +34.78% -64.37%
Sales 2021 0.07 Sales 2022 0.14 Capitalization 3.5M
Net income 2021 -3M Net income 2022 -18M EV / Sales 2021 112,421,804 x
Net Debt 2021 7.1M Net Debt 2022 7.15M EV / Sales 2022 78,689,579 x
P/E ratio 2021
-0.3 x
P/E ratio 2022
-0.14 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 75.3%
More Fundamentals * Assessed data
Dynamic Chart
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval CI
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration CI
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Endonovo Therapeutics, Inc. Announces Final Stages to Receive Taiwan FDA License to Distribute in Taiwan CI
Endonovo Announces Distribution Agreement with Academy Medical CI
Endonovo Partners with International Distributor for SofPulse Line CI
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as A Listed Public Company CI
Endonovo Therapeutics, Inc. agreed to Spin-Off Medical Device Division of Endonovo Therapeutics. CI
More news
1 day+34.78%
1 week+34.78%
Current month-11.43%
1 month-11.43%
3 months-63.53%
6 months-70.48%
Current year-64.37%
More quotes
1 week
0.00
Extreme 0.002
0.01
1 month
0.00
Extreme 0.002
0.01
Current year
0.00
Extreme 0.001
0.01
1 year
0.00
Extreme 0.001
0.02
3 years
0.00
Extreme 0.001
0.06
5 years
0.00
Extreme 0.001
24.65
10 years
0.00
Extreme 0.001
13 590.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 12-02-29
Chief Operating Officer 53 -
Investor Relations Contact - 14-04-30
Members of the board TitleAgeSince
Chief Executive Officer 59 12-02-29
More insiders
Date Price Change Volume
24-03-28 0.0031 +34.78% 40,462,339
24-03-27 0.0023 0.00% 10,001,873
24-03-26 0.0023 -25.81% 2,674,902
24-03-25 0.0031 -8.82% 181,280
24-03-22 0.0034 +47.83% 5,361

Delayed Quote OTC Markets, March 28, 2024 at 03:54 pm EDT

More quotes
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
More about the company
  1. Stock
  2. Equities
  3. Stock Endonovo Therapeutics, Inc. - OTC Markets